EFFICACY OF RESLIZUMAB DOSE ESCALATION IN PATIENTS WITH SEVERE ASTHMA AND PERSISTENT SPUTUM EOSINOPHILIA DESPITE STANDARD DOSE THERAPY.
- Registry ID
- C38072-AS-60323
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- ST JOSEPHS HOSPITAL HAMILTON
- Start date
- 2021-09-20
- Last update
- 2020-12-17
Conditions
- EOSINOPHILIC ASTHMA
- ASTHMA
Related clinical trials
- A MULTINATIONAL, INVESTIGATOR-INITIATED, PARALLEL GROUP, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3B SUPERIORITY TRIAL ASSESSING THE EFFECT OF DUPILUMAB ON INDUCING CLINICAL REMISSION OUTCOMES IN AT-RISK TYPE-2 INFLAMMATORY ASTHMA (HOTHOT)
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2A STUDY OF ARO-RAGE INHALATION SOLUTION TO ASSESS EFFICACY ON SMALL AIRWAY DYSFUNCTION IN ALLERGEN-INDUCED MILD ASTHMA
- A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, 52-WEEK STUDY, TO INVESTIGATE THE EFFICACY AND SAFETY OF BRENIPATIDE COMPARED WITH PLACEBO FOR THE TREATMENT OF ADULT PARTICIPANTS WITH UNCONTROLLED MODERATE TO SEVERE ASTHMA
- PAXT: PULMONARY IMAGING OF MILD ASTHMA USING 129-XENON MRI AND TC-99-LABELED-CARBON-IMAGING (TC99CIMAGING)
- REVERSE LUNG AIRWAY AND VASCULAR REMODELING IN ASTHMA REMISSION (RENORM)
- TEZEPELUMAB IN THE TREATMENT OF EMERGENCY ROOM ASTHMA IN ADULTS (TERAA): A PHASE 4 DOUBLE-BLINDED, PARALLEL-GROUP RANDOMIZED CONTROL TRIAL WITH AN OPEN LABEL EXTENSION
View on source registry